1) Strategy & Leadership - Edwards Lifesciences reported a strong Q4 2025 with sales growth of 11.6% and a full-year growth of 10.7%. - The company’s strategy focuses on three key elements: prioritizing Structural Heart, addressing complex patient needs, and innovating within the market. - The leadership transition includes Jerrianne Sarte as the new Senior VP of Investor Relations, emphasizing continuity and expertise in medtech.

2) Financial & Segment Results - Total Q4 sales reached $1.57 billion, with TAVR sales of $1.16 billion, growing 10.6% YoY. - TMTT (Transcatheter Mitral and Tricuspid Therapies) grew over 40% to $156 million, contributing to a full-year total exceeding $500 million. - Surgical product sales were $254 million, a 2% increase YoY, with full-year sales surpassing $1 billion for the first time. - Adjusted EPS for Q4 was $0.58, lower than expected due to increased spending on patient access initiatives.

3) Operational & Product Plans - Key advancements include the launch of SAPIEN M3 and scaling of EVOQUE, with expectations to achieve $2 billion in TMTT revenue by 2030. - The company is focusing on expanding indications and pioneering new therapies, particularly in structural heart failure and aortic regurgitation. - A partnership with the American Heart Association aims to enhance awareness and treatment of heart valve disease.

4) Guidance & Outlook - Edwards Lifesciences expects 8% to 10% sales growth and EPS guidance of $2.90 to $3.05 for 2026. - The company anticipates a potential tailwind from an updated national coverage determination (NCD) for TAVR, with a focus on timely access to care. - The guidance reflects confidence in continued growth despite a higher bar set by 2025's performance.

5) Problems / Headwinds - The company faced challenges with a higher-than-expected tax rate and increased SG&A expenses, which impacted EPS. - There is uncertainty surrounding the outcomes of the PROGRESS trial for moderate aortic stenosis patients, which could affect future growth opportunities.

Bottom line: Edwards Lifesciences is positioned for sustained growth, driven by a robust product pipeline and strategic focus on structural heart therapies, despite facing some operational headwinds. The company’s strong performance in 2025 sets a solid foundation for achieving its ambitious targets in 2026 and beyond.